Experience with indolecarbinol used to treat mastopathy

Abstract

Purpose. Determine efficacy of a drug in patients with pain syndrome in mastopathy. Objectives. Evaluate the efficacy of the drug by measuring its effect on the pain intensity in the mammary glands, tissue density of the mammary glands, changes in size of existing cysts and fibroadenomas performed after 3and 6-month administration of the drug, and 12-month discontinuation of treatment, provided that the prophylactic 3-month course of Indinol Forto was taken.Material and methods. We examined 60 patients, who applied to the Breast Pathology Department of the National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakova, and complained of pain in the mammary glands, mainly in the second phase of the menstrual period. The age of the patients ranged from 21 to 55 years (median, 36.3 years).Results: 3-month use of the drug showed a decrease in pain intensity in half of the patients (51%), a decrease in palpation density in 58% of patients, a decrease in cyst size in 24 patients, a decrease in echo density in 27% of patients. The size of fibroadenodoimas did not change in 100% of cases. The drug showed efficacy in all age groups. During the control examination (third visit), a decrease in pain intensity was observed in 85% of patients 6 months later. Palpation density decreased in 70% of patients. The size of cysts and fibroadenomas did not change in comparison with the third visit. Echo density of the tissue decreased in 55% of women. 3 (5%) of 60 patients refused to take the drug during the 4th month, due to dyspeptic disorders, 2 (3%) patients of reproductive age complained of lengthening of the menstrual period also after the 4th month of taking the drug. No recurrence of the disease was detected as a result of a 6-month follow-up of 11 patients receiving Indinol Forto after surgical treatment of fibroadenomas. 57 patients made the fourth visit 12 months later. All patients received a preventive 3-month course of Indinol Forto. 17 (30%) patients had no pain in the mammary glands no longer. 18 patients reported a periodic pain in the mammary glands. 38% of women reported that soreness was rare and completely absent while taking the drug. 11 patients showed no recurrence of fibroadenomas after surgery. There was no significant change in the size of fibroadenomas in non-operated patients. Slight cystic growth was reported in two patients. After 12 months, punctured cysts did not exceed 1 cm in diameter in six patients, who underwent medical and diagnostic puncture of large cysts. The scheduled mammography and ultrasound imaging showed a steady decrease in echographic and mammographic density.